Antiphospholipid syndrome: Reversal of antiphosphatidylserine/prothrombin-induced activated protein C resistance.

[1]  V. Pengo.  Interaction between Antiphospholipid Antibodies and Protein C Anticoagulant Pathway: A Narrative Review , 2022, Seminars in Thrombosis and Hemostasis.

[2]  H. ten Cate,et al.  Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies , 2021, Journal of thrombosis and haemostasis : JTH.

[3]  V. Pengo,et al.  Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review. , 2020, Blood reviews.

[4]  V. Pengo,et al.  Insight into the hypercoagulable state of high‐risk thrombotic APS patients: Contribution of aβ2GPI and aPS/PT antibodies , 2020, Journal of thrombosis and haemostasis : JTH.

[5]  T. Ortel,et al.  Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis , 2020, Journal of thrombosis and haemostasis : JTH.

[6]  J. Ahmed,et al.  Protein C Deficiency as a Risk Factor for Stroke in Young Adults: A Review , 2020, Cureus.

[7]  V. Pengo,et al.  Tetra positive thrombotic antiphospholipid syndrome: Major contribution of anti‐phosphatidyl‐serine/prothrombin antibodies to lupus anticoagulant activity , 2020, Journal of thrombosis and haemostasis : JTH.

[8]  A. Tincani,et al.  Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. , 2018, Blood.

[9]  T. Ortel,et al.  Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[10]  M. Fisher.  Brain Regulation of Thrombosis and Hemostasis: From Theory to Practice , 2013, Stroke.

[11]  Sabino Iliceto,et al.  Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. , 2011, Blood.

[12]  S. Iliceto,et al.  Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome , 2010, Journal of thrombosis and haemostasis : JTH.

[13]  T. Ortel,et al.  Update of the guidelines for lupus anticoagulant detection , 2009, Journal of thrombosis and haemostasis : JTH.

[14]  B. Mahmoodi,et al.  Hereditary Deficiency of Protein C or Protein S Confers Increased Risk of Arterial Thromboembolic Events at a Young Age: Results From a Large Family Cohort Study , 2008, Circulation.

[15]  S. Iliceto,et al.  Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity , 2006, Thrombosis and Haemostasis.

[16]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[17]  A. Biasiolo,et al.  Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. , 2003, Clinical chemistry.

[18]  P. Hogg,et al.  Dependence on Prothrombin for Inhibition of Activated Protein C Activity by Lupus Antibodies , 2000, Thrombosis and Haemostasis.

[19]  S. Kitchen,et al.  Lipid composition of seven APTT reagents in relation to heparin sensitivity , 1999, British journal of haematology.

[20]  José A Fernández,et al.  Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. , 1999, Blood.

[21]  T. Barbui,et al.  Differential effects of anti-beta2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. , 1998, Blood.

[22]  G. Ruiz-Argüelles,et al.  Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome , 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[23]  M. Blombäck,et al.  A new variant of interaction between phospholipid antibodies and the protein C system , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[24]  S. Lo,et al.  Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant , 1990, British journal of haematology.

[25]  M. Greaves,et al.  Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies , 1990, British journal of haematology.

[26]  R. Williams,et al.  Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. , 1990, Thrombosis research.

[27]  J. Miletich,et al.  Human coagulation factor Va is a cofactor for the activation of protein C. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Y. Kanakura,et al.  The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. , 2006, Haematologica.

[29]  E. Romond,et al.  Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. , 1989, Blood.